Elesclomol

Drug Profile

Elesclomol

Alternative Names: Elesclomol sodium; STA-4783

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Synta Pharmaceuticals
  • Class Antineoplastics; Hydrazines; Ketones; Small molecules; Thiones
  • Mechanism of Action Apoptosis stimulants; Chelating agents; HSP70 heat shock protein stimulants; Reactive oxygen species stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Sarcoma

Most Recent Events

  • 15 Mar 2016 Synta Pharmaceuticals enter into an asset purchase agreement with a third party (Synta Pharmaceuticals, Form 10-K, March 2016)
  • 13 Aug 2015 Elesclomol is still in phase II trials for Ovarian cancer (Combination therapy, Second-line therapy or greater) in the USA
  • 09 Apr 2014 Discontinued - Phase-I for Prostate cancer (combination therapy, hormone refractory, late-stage disease, metastatic disease) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top